Effect Of L-Carnitine On Urinary Il-18 And Gfr In Patient Receiving Cisplatin-Based Regimen
Keywords:Cisplatin, Renal toxicity, L-carnitine
AbstractBackground: Nephrotoxicity is a major dose-limiting side effect facing cisplatin-based chemotherapy of a wide variety of cancers. Acute kidney injury occurs after cisplatin chemotherapy in approximately 30% of patients where severe and lifelong nephrotoxicity can result regardless of the use of powerful hydration with normal saline.In spite of scientific efforts to find relatively less toxic but equally effective substitutes, cisplatin continues to be widely involved in chemotherapy as first line antitumor agent. Apoptosis and necrosis, due to DNA damage response pathways, oxidative stress in association with severe inflammatory response and caspase activation, are the major sources of acute kidney injury due to cisplatin. L-carnitine with their antioxidant, anti-inflammatory and to some extent antiapoptotic effects may have ameliorative effect on nephrotoxicity. Aim: To assess the effects of L-carnitine in protection from cisplatin–induced nephrotoxicity in cancer patients. Patients and methods:28 patients were participated in the study and successfully completed their treatment cycles. They were randomized into two groups (N=14 in each). In group I, patients received six cycles of cisplatin based regimen with 21 days-intervals. In group II, patients received L-carnitine(500 mg oral tablet twice daily) plus cisplatin based regimen. GFR (Modification of Diet in renal Diseases formula) was measured at base line and 21 days after 1, 2, 4 and 6 cycles but IL-18 was measured at base line and 1 day after 1, 2, 4 and 6 cycles of cisplatin based regimen. Results:In patients of group I, cisplatin-based regimen caused significant (P<0.05) increment in serum creatinine and urea levels, highly significant (P<0.01) increment in serum urinary IL-18 levels, and significant (P<0.05) decrement in GFR in comparison to base line levels. Conclusions:Each of L-carnitine significantly ameliorated nephrotoxicity in patients that received cisplatin.
Lebwohl D, Canetta R. (1998): Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer. 34:1522–34.
Pabla N, Dong Z. (2008): Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 73, 994–1007.
Goldstein RS, Mayor GH. (1983): Minireview. The nephrotoxicity of cisplatin. Life Sci. 32, 685–690.
Yao X, Panichpisal K, Kurtzman N, et al. (2007): Cisplatin nephrotoxicity: a review, Am. J. Med. Sci., 334, 115-124.
Miller RP, Tadagavadi RK, Ramesh G, et al. (2010): Mechanisms of cisplatin nephrotoxicity. Toxins 2, 2490–2518.
Tein I, Bukovac SW, Xie ZW. (1996): Characterization of the human plasmalemmalcarnitine transporter in cultured skin fibroblasts. Arch. Biochem. Biophys. 329, 145–155.
Engel AG, Rebouche CJ. (1984): Carnitine metabolism and inborn errors. J. Inher. Metabol. Dis. 7, 38–43.
Steiber A, Kerner J, Hoppel CL. (2004): Carnitine: a nutritional, biosynthetic, and functional perspective. Mol. Aspects Med. 25, 455– 473.
Stewart DJ, Morgan Jr LR, Verma S, et al. (1995): Pharmacology, relative bioavailability, and toxicity of three different oral cyclophosphamide preparations in a randomized, cross-over study. Invest. New Drugs 13, 99–107.
Malaguarnera M, Risino C, Gargante MP, et al. (2006): Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia. World J. Gastroenterol. 12, 4541–4545.
Heuberger W, Berardi S, Jacky E, et al. (1998): Increased urinary excretion of carnitine in patients treated with cisplatin. Eur. J. Clin. Pharmacol. 54, 503–508.
Arafa HM, (2008): Carnitine deficiency aggravates carboplatin nephropathy through deterioration of energy status, oxidant/antioxidant balance, and inflammatory endocoids. Toxicology 254, 51– 60.
Sayed-Ahmed MM, Khattab M, Khalifa A, et al. (1999): And Osman, A.M: Potenial promise of using L-carnitine and Coenzyme Q10 as protective agents against cisplatin-induced nephrotoxicity. J. Egypt. Natl. Cancer Inst. 11, 167–173.
Chang B, Nishikawa M, Sato E, et al. (2002): L-carnitine inhibits cisplatin-induced injury of the kidney and small intestine. Arch. Biochem. Biophys. 405, 55–64.
Yürekli Y, Ünak P, Yenisey C, et al. (2011): L-Carnitine Protection Against Cisplatin Nephrotoxicity In Rats: Comparison with Amifostin Using Quantitative Renal Tc 99m DMSA Uptake Mol Imaging RadionuclTher. 20(1): 1–6.
Levey AS, Eckardt KU, Tsukamoto Y, et al. (2005): Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67: 2089–2100.
Levey AS, Coresh J, Greene T, et al. (2007): Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration Standardized serum creatinine rate with values. ClinChem 53, 766-772.
Larsson A, Malm J, Grubb A, et al. (2004): Calculation of glomerular filtration rate overexpressed in mL / min from plasma cystatin C values in mg / L. Scand J Clin Lab Invest 64, 25-30.
Okamura H, Tsutsi H, Komatsu T, et al. (1995): Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature. 378 : 88 –91.
Nakanishi K, Yoshimoto T, Tsutsui H, et al. (2001): Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 12 : 53 –72 .
Neighbors M, Xu X, Barrat FJ, et al. (2001): A critical role for interleukin 18 in primary and memory effector responses to Listeria monocytogenes that extends beyond its effects on interferon gamma production. J Exp Med 194: 343 –354.
Mehta RL. (2006): Urine IL-18 levels as a predictor of acute kidney injury in intensive care patients. Nat ClinPractNephrol 2:252-253.
Parikh CR, Jani A, Melnikov VY, et al. (2004): Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis 43:405-414.
Bodnara L, Wcisloa G, Gasowska-Bodnarb A, et al. (2008): protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: A randomised phase II study. Europ J Canc 44, 2608–2614.
Ramesh G, Reeves WB. (2002): TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest. 110:835–42.
Wu H, Craft ML, Wang P, et al. (2008): IL-18 contributes to renal damage after ischemia-reperfusion. J Am Soc Nephrol.19:2331 _4.
Parikh CR, Abraham E, Ancukiewicz M, et al. (2005): Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the ICU. J Am SocNephrol 16:3046-3052.
Mister M, Noris M, Szymczuk J, et al. (2002): Propionyl-L-carnitine prevents renal function deterioration due to ischemia/reperfusion. Kidn Intern. 61, 1064–1078
Chapela SP, Kriguer N, Fernandez E.H, et al. (2009): Involvement of L-Carnitine in Cellular Metabolism: Beyond Acyl-CoA Transport. Mini-Reviews in Medicinal Chemistry. 9:1518–1526.
Tufekci O, Gunes D, Ozog˘ ul C, et al. (2009): Evaluation of the effect of acetyl L-carnitine on experimental cisplatin nephrotoxicity. Chemoth 55, 451–459.